Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.

Original languageEnglish (US)
Pages (from-to)432-437
Number of pages6
JournalClinics in Dermatology
Volume31
Issue number4
DOIs
StatePublished - Jul 2013
Externally publishedYes

Fingerprint

Localized Scleroderma
Systemic Scleroderma
Terminology
Diffuse Scleroderma
Connective Tissue Diseases
Mortality
Expert Testimony
Rare Diseases
Morbidity
Skin
Research

ASJC Scopus subject areas

  • Dermatology

Cite this

Scleroderma : Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies. / Fett, Nicole.

In: Clinics in Dermatology, Vol. 31, No. 4, 07.2013, p. 432-437.

Research output: Contribution to journalArticle

@article{10e490d5d4b846188a4303e1436e652c,
title = "Scleroderma: Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies",
abstract = "Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.",
author = "Nicole Fett",
year = "2013",
month = "7",
doi = "10.1016/j.clindermatol.2013.01.010",
language = "English (US)",
volume = "31",
pages = "432--437",
journal = "Clinics in Dermatology",
issn = "0738-081X",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Scleroderma

T2 - Nomenclature, etiology, pathogenesis, prognosis, and treatments: Facts and controversies

AU - Fett, Nicole

PY - 2013/7

Y1 - 2013/7

N2 - Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.

AB - Scleroderma refers to a heterogeneous group of autoimmune fibrosing disorders. The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently accepted disease subtypes. Major advances have been made in the molecular studies of morphea and systemic sclerosis; however, their etiologies and pathogenesis remain incompletely understood. Although morphea and systemic sclerosis demonstrate activation of similar inflammatory and fibrotic pathways, important differences in signaling pathways and gene signatures indicate they are likely biologically distinct processes. Morphea can cause significant morbidity but does not affect mortality, whereas systemic sclerosis has the highest disease-specific mortality of all autoimmune connective tissue diseases. Treatment recommendations for morphea and systemic sclerosis are based on limited data and largely expert opinions. Current collaborative efforts in morphea and systemic sclerosis research will hopefully lead to better understanding of the etiology and pathogenesis of these rare and varied diseases and improved treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84879567198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879567198&partnerID=8YFLogxK

U2 - 10.1016/j.clindermatol.2013.01.010

DO - 10.1016/j.clindermatol.2013.01.010

M3 - Article

C2 - 23806160

AN - SCOPUS:84879567198

VL - 31

SP - 432

EP - 437

JO - Clinics in Dermatology

JF - Clinics in Dermatology

SN - 0738-081X

IS - 4

ER -